Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Wnt inhibitor
KY02111 is a potent and selective Wnt signaling pathway inhibitor discovered by a cell-based screening, which promotes differentiation of hESCs/iPSCs to cardiomyocytes when used at the second stage of differenitation.- Abinayaselvi Murugan, .et al. , bioRxiv, 2024, February 22
-
PARP inhibitor
XAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 μM for TNKS1 and TNKS2 respectively).- Esteban Zamudio-Martínez, .et al. , Cell Commun Signal, 2025, Nov 5;23:477 PMID: 41194181
- Shizu Aikawa, .et al. , EMBO J, 2017, Jul 14; 36(14): 2146-2160 PMID: 28588064
- Mikaël M. Martino, .et al. , Nat Commun, 2016, 7: 11051 PMID: 27001940
-
Wnt/beta-catenin inhibitor
ICG-001 is a specific inhibitor of Wnt/β-catenin signaling pathway that inhibits β-catenin/cyclic AMP response element-binding (CREB) protein transcription (IC50=3 microM) .- Hong Gao, .et al. , Sci Rep, 2024, Oct 15;14(1):24182 PMID: 39406776
- Yun-Sheng Chen, .et al. , Research Square, 2024, August 16th
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Seonmin Choi, .et al. , Yonsei Med J, 2021, Nov;62(11):1042-1051 PMID: 34672138
- Jasper C.Munro, .et al. , Livest Sci, 2019, 229 (2019) 159-169
- Kim JH, .et al. , Cell Rep, 2019, May 14;27(7):2105-2118.e5 PMID: 31091449
- Yamaoka R, .et al. , J Surg Oncol, 2018, Sep;118(4):664-674 PMID: 30196535
- Aida Y, .et al. , In Vitro Cell Dev Biol Anim, 2018, Jun;54(6):468-476 PMID: 29785536
-
PORCN/Wnt inhibitor
Wnt-C59 is a very potent and highly selective Wnt signaling antagonist with an IC50 ~ 74 pM in the Wnt signaling reporter assay.- Laksitorini MD, .et al. , Sci Rep, 2019, Dec 23;9(1):19718 PMID: 31873116
-
Wnt agonist 1
Wnt agonist 1 is a cell-permeable Wnt signaling activator. It nduces beta-catenin and TCF-dependent transcriptional activity with EC50 value of 0.7 uM.- Lingling Chen, .et al. , Biochem Pharmacol, 2024, Nov 29:232:116688 PMID: 39617210
- Abinayaselvi Murugan, .et al. , bioRxiv, 2024, February 22
- Zhao-Hui Chen, .et al. , Breast Cancer Res, 2023, 25: 22 PMID: 36829181
-
CBP/beta-catenin antagonist
PRI-724 is the second-generation, potent and specific inhibitor of CBP/β-Catenin complex, and a modulator of the β-Catenin dependent canonical Wnt signaling pathway in cancer stem cells.
- Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682
-
PORCN inhibitor
LGK974 is a highly potent, selective and orally bioavailable Porcupine inhibitor (Wnt signaling antagonist) with an IC50 <1 nM in the Wnt signaling reporter assay and Porcupine binding assay.- Uxia Gurriaran-Rodriguez, .et al. , Sci Adv, 2024, Dec 13;10(50):eado5914 PMID: 39661666
- Sho Tsukamoto, .et al. , Development, 2023, Aug 1;150(15):dev201734 PMID: 37539462
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- A-Ri Cho, .et al. , Sci Rep, 2022, Apr 29;12(1):7013 PMID: 35487932
- Yang JM, .et al. , Toxicology, 2018, Dec 1;410:65-72 PMID: 30205152
- E Lemieux, .et al. , Oncogene, 2015, Sep 17; 34(38): 4914-4927 PMID: 25500543
-
Wnt inhibitor
JW74 is an efficient and specific inhibitor of the canonical Wnt signaling. JW74 shows a reduction of canonical Wnt signaling in the ST-Luc assay with IC50 values of 790 nM.- Yang JM, .et al. , Toxicology, 2018, Dec 1;410:65-72 PMID: 30205152
-
Wnt inhibitor
IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription.- Yuichi Akaba, .et al. , iScience, 2025, Oct 16;28(11):113789 PMID: 41244585
- Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921
-
Wnt inhibitor
IWP-3 is an inhibitor of Wnt production. Blocks Wnt pathway activity in vitro ( IC?????€ = 40 nM). IWP-3 inactivates Porcupine (Porcn), a membrane-bound O-acyltransferase responsible for palmitoylating Wnt proteins, which is essential for their signaling ability and secretion. Through blockade of Wnt signaling, IWP-3 has been used to promote cardiomyocyte generation from human embryonic stem cells (EC?????€ = 1.2 μM). -
Potent porcupine inhibitor
Porcn-IN-1 is potent porcupine inhibitor with an IC50 of 0.5??0.2 nM. - Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.
- EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
-
Wnt/β-catenin agonist
Wnt/β-catenin agonist 1 is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM. -
FZD4 agonist
FzM1.8 is an allosteric agonist of the Frizzled receptor FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K. - Salinomycin is an antibacterial and coccidiostat ionophore therapeutic drug.
-
Wnt pathway activator
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate; with EC50 of 0.63 uM in TCF-Luciferase assay. - Cardiogenol C is a diaminopyrimidine compound that induces the differentiation of MHC- (myosin heavy chain) positive cardiomyocytes from embryonic stem cells with an EC50 value of 0.1 uM. Cardiogenol C upregulates cardiac markers and induces cardiac functional properties in lineage-committed progenitor cells.
-
Wnt/beta-catenin inhibitor
Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator with EC50 of 4.61 ?? 1.29 uM; also is an inhibitor of Wnt/beta-catenin signaling. - Prodigiosin (Prodigiosine) is a secondary metabolite of Symbiotic bacteria, with anti-fungal and anti-cancer activity.
-
WNT Inhibitor
WNTinib is a selective WNT signaling inhibitor targeting mutated β-catenin (CTNNB1) in hepatocellular carcinoma (HCC). By effectively disrupting the oncogenic Wnt pathway, WNTinib inhibits key kinases such as KIT and MAPK, leading to the reduction of EZH2 activation. This compound is suitable for research applications focused on cancer biology and the mechanisms of liver tumorigenesis. -
Wnt/β-catenin Inhibitor
KWZY-11 is a potent Wnt/β-catenin inhibitor that effectively modulates the associated signaling pathway. This compound demonstrates strong biological activity by inducing DNA damage and promoting apoptosis specifically in MDA-MB-231 breast cancer cells. Its dual inhibition of PARP and CDK6 enhances its potential applications in cancer research, particularly for therapeutic strategies targeting tumor cell proliferation. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin agonist 2 is a potent activator of the Wnt/β-catenin signaling pathway. This compound effectively stimulates Wnt signaling, making it a valuable tool for investigating the molecular mechanisms underlying diseases associated with aberrant signal transduction. Researchers can utilize this reagent in studies focused on developmental biology, cancer research, and regenerative medicine, where modulation of the Wnt pathway plays a critical role. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin Agonist 3 is a potent activator of the Wnt/β-catenin signaling pathway. This compound enhances β-catenin-mediated transcriptional activity, making it valuable for research related to bone density disorders such as osteoporosis. Its application in cellular and animal models provides insights into the molecular mechanisms underlying Wnt signaling and offers potential therapeutic avenues for bone-related diseases. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
Wnt/β-catenin Signaling Pathway Inhibitor
Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies. -
Wnt/β‐Catenin Activator
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide derived from Maca (Lepidium meyenii Walp.) that acts as a Wnt/β-catenin activator. This compound promotes the osteogenic differentiation of mesenchymal stem cells and enhances bone formation by activating the canonical Wnt/β-catenin signaling pathway. It serves as a valuable reagent for research focused on osteoporosis and related conditions. -
Wnt Inhibitor
PTK7/β-catenin-IN-2 is a potent inhibitor of the PTK7/β-catenin interaction, effectively disrupting Wnt/β-catenin signaling with an IC50 of 5.6 μM. This inhibition impairs cell growth mediated by the Wnt pathway and demonstrates potential anticancer activity. Additionally, PTK7/β-catenin-IN-2 exhibits inhibitory effects on the p53-MDM2 interaction, with an IC50 of 157.1 μM, making it valuable for research focused on cancer therapies and signaling pathway modulation. -
Wnt/β-catenin Agonist
SLD1121 is a potent agonist of the Wnt/β-catenin signaling pathway, specifically targeting LRP6 with an inhibition constant (Kd) ranging from 4.52 to 7.49 nM. By interacting with the intracellular domain of LRP6, SLD1121 stabilizes the receptor, enhances its nuclear translocation, and promotes its association with β-catenin, TCF4, or LEF1, leading to the upregulation of Wnt-regulated and stem cell-associated genes. Notably, SLD1121 facilitates the transition of hair follicles from the telogen to anagen phase in the mouse hair growth cycle, making it a valuable reagent for research focused on hair loss and regenerative medicine. -
Wnt/β-catenin Signal Inhibitor
KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression.
